Abstract
This study was conducted to determine whether drugs used for conventional treatments of pregnant women with antiphosholipid syndrome might be able to restore the gonadotrophin-releasing hormone (GnRH)-induced secretion of placental human chorionic gonadotrophin (HCG) in vitro. We tested this hypothesis using a modified enzyme-linked immunosorbent assay (ELISA) and an in-vitro placental culture system. Pharmacological dose of low molecular weight heparin (20 IU/ml) significantly (P < 0.02) reduced the antiphospholipid antibody (aPL) binding in the ELISA and was able to restore GnRH-induced HCG secretion (P < 0.05) in presence of aPL-containing sera. Low-dose aspirin (0.03 M) did not modify aPL binding in the ELISA, but partially restored HCG secretion (P < 0.05). These observations may help to explain the role of these treatments in antiphospholipid syndrome.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents / pharmacology
-
Antibodies, Antiphospholipid / metabolism
-
Antibodies, Antiphospholipid / pharmacology*
-
Antiphospholipid Syndrome / blood*
-
Aspirin / administration & dosage
-
Aspirin / pharmacology*
-
Betamethasone / pharmacology
-
Cell Count
-
Cells, Cultured
-
Chorionic Gonadotropin / metabolism*
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Gonadotropin-Releasing Hormone / pharmacology
-
Heparin, Low-Molecular-Weight / administration & dosage
-
Heparin, Low-Molecular-Weight / pharmacology*
-
Humans
-
Methylene Blue
-
Placenta / drug effects
-
Placenta / metabolism*
-
Pregnancy
-
Trophoblasts / drug effects
-
Trophoblasts / physiology
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Antiphospholipid
-
Chorionic Gonadotropin
-
Heparin, Low-Molecular-Weight
-
Gonadotropin-Releasing Hormone
-
Betamethasone
-
Aspirin
-
Methylene Blue